ORAMED PHARMACEUTICALS INC logo

ORMP

ORAMED PHARMACEUTICALS INC

$2.17

Earnings Summary

Revenue
$0.6Mn
Net Profits
$-2.92Mn
Net Profit Margins
-482.78%

Highlights

Revenue:

ORAMED PHARMACEUTICALS INC’s revenue fell -1.15% since last year same period to $0.6Mn in the Q1 2018. On a quarterly growth basis, ORAMED PHARMACEUTICALS INC has generated -1.15% fall in its revenue since last 3-months.

Net Profits:

ORAMED PHARMACEUTICALS INC’s net profit jumped 8.39% since last year same period to $-2.92Mn in the Q1 2018. On a quarterly growth basis, ORAMED PHARMACEUTICALS INC has generated -15.21% fall in its net profits since last 3-months.

Net Profit Margins:

ORAMED PHARMACEUTICALS INC’s net profit margin jumped 7.33% since last year same period to -482.78% in the Q1 2018. On a quarterly growth basis, ORAMED PHARMACEUTICALS INC has generated -16.55% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the ORAMED PHARMACEUTICALS INC post its latest quarter earnings

EPS Estimate Current Quarter
-0.24
EPS Estimate Current Year
-0.24

Highlights

EPS Estimate Current Quarter:

ORAMED PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current quarter stand at -0.24 - a -23.28% fall from last quarter’s estimates.

EPS Estimate Current Year:

ORAMED PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current year stand at -0.24.

Key Ratios

Key ratios of the ORAMED PHARMACEUTICALS INC post its Q1 2023 earnings

Earning Per Share (EPS)
0
Return on Assets (ROA)
-0.15
Return on Equity (ROE)
-0.24

Highlights

Earning Per Share (EPS):

ORAMED PHARMACEUTICALS INC’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the ORAMED PHARMACEUTICALS INC has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ORAMED PHARMACEUTICALS INC’s return on assets (ROA) stands at -0.15.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ORAMED PHARMACEUTICALS INC’s return on equity (ROE) stands at -0.24.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-01-11
-0.16
-0.22
-37.5%
2021-04-13
-0.17
-0.17
0%
2021-11-24
-0.18
-0.21
-16.67%
2021-07-14
-0.2
-0.17
15%

Company Information

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsulefor the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.

Organisation
ORAMED PHARMACEUTICALS INC
Headquarters
1185 Avenue of the Americas, New York, NY, United States, 10036
Employees
0
Industry
Health Technology
CEO
Nadav Kidron